Eur Urol Focus:残疾男性的前列腺特异性抗原检测

2021-08-12 AlexYang MedSci原创

残疾患者是一个独特的少数群体。在这一人群中,前列腺特异性抗原(PSA)检测的发生率是未知的。

残疾患者是一个独特的少数群体。在这一人群中,前列腺特异性抗原(PSA)检测的发生率是未知的。

近期,有研究人员比较了美国有残疾和无残疾的男性的PSA检测率和相关预测因素

研究人员对2012年、2013年、2017年和2019年的健康信息全国趋势调查(HINTS)进行了横断面研究,对有报告残疾的男性进行了调查。

研究人员根据他们报告的残疾(无、残疾、聋和盲)情况不同,将整个队列的基线人口统计学进行了分层。每种残疾都单独相互间进行了比较,并与没有残疾的队列进行了合并分析。多变量逻辑回归模型确定了残疾男性与非残疾男性相比在临床上有显著意义的PSA检测预测因素。

总体而言,研究人员对782名(15%)残疾男性与4569名(85%)非残疾男性进行了比较。结果发现,残疾男性的年龄较大,中位数(四分位数范围)为65(56-75)岁,非残疾男性为57(43-67)岁(P<0.001)。在多变量分析中,有任何残疾的男性接受PSA检测(几率比(OR)为0.77,95%置信区间(CI)为0.62-0.96,P=0.018)的可能性低。与PSA检测增加有关的变量包括年龄、有医疗服务提供者、医疗保险和与伴侣同住

综上所述,美国残疾男性在PSA检测方面存在不平等现象,尤其是聋哑人,他们不太可能接受PSA检测。仍旧需要进一步研究来确定和处理在这一独特人群中实施平等PSA检测的任何障碍。总之,在美国,有报告残疾的男性比没有报告残疾的患者接受PSA检测的可能性小

原始出处:

Joon Yau Leong, Ruben Pinkhasov, Thenappan Chandrasekar et al. Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey. Eur Urol Focus. Jul 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010872, encodeId=e2c120108e2b8, content=<a href='/topic/show?id=545f3251845' target=_blank style='color:#2F92EE;'>#前列腺特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32518, encryptionId=545f3251845, topicName=前列腺特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 06 21:08:20 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899510, encodeId=873218995102f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 11 16:08:20 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957852, encodeId=3e56195e852b5, content=<a href='/topic/show?id=41cb6e95555' target=_blank style='color:#2F92EE;'>#特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67955, encryptionId=41cb6e95555, topicName=特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 24 07:08:20 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623401, encodeId=2498162340132, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Aug 14 12:08:20 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010872, encodeId=e2c120108e2b8, content=<a href='/topic/show?id=545f3251845' target=_blank style='color:#2F92EE;'>#前列腺特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32518, encryptionId=545f3251845, topicName=前列腺特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 06 21:08:20 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899510, encodeId=873218995102f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 11 16:08:20 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957852, encodeId=3e56195e852b5, content=<a href='/topic/show?id=41cb6e95555' target=_blank style='color:#2F92EE;'>#特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67955, encryptionId=41cb6e95555, topicName=特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 24 07:08:20 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623401, encodeId=2498162340132, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Aug 14 12:08:20 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010872, encodeId=e2c120108e2b8, content=<a href='/topic/show?id=545f3251845' target=_blank style='color:#2F92EE;'>#前列腺特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32518, encryptionId=545f3251845, topicName=前列腺特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 06 21:08:20 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899510, encodeId=873218995102f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 11 16:08:20 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957852, encodeId=3e56195e852b5, content=<a href='/topic/show?id=41cb6e95555' target=_blank style='color:#2F92EE;'>#特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67955, encryptionId=41cb6e95555, topicName=特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 24 07:08:20 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623401, encodeId=2498162340132, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Aug 14 12:08:20 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010872, encodeId=e2c120108e2b8, content=<a href='/topic/show?id=545f3251845' target=_blank style='color:#2F92EE;'>#前列腺特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32518, encryptionId=545f3251845, topicName=前列腺特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 06 21:08:20 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899510, encodeId=873218995102f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 11 16:08:20 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957852, encodeId=3e56195e852b5, content=<a href='/topic/show?id=41cb6e95555' target=_blank style='color:#2F92EE;'>#特异性抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67955, encryptionId=41cb6e95555, topicName=特异性抗原)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 24 07:08:20 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623401, encodeId=2498162340132, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Aug 14 12:08:20 CST 2021, time=2021-08-14, status=1, ipAttribution=)]

相关资讯

BMC Urol:晚期前列腺癌患者服用阿帕鲁胺后出现皮疹,需要特殊处理吗?

临床中,常在日本的前列腺癌(PC)患者中观察到较高的阿帕鲁胺相关皮疹发生率。为此,研究人员综合分析了来自2项全球3期研究(SPARTAN和TITAN)和1期研究56021927PCR1008的日本患者

J Urol:经直肠和经会阴前列腺活检对健康的影响评估

经直肠前列腺活检是对具有临床重要前列腺癌(Gleason评分≥7)风险因素(如前列腺特异性抗原(PSA)升高或数字直肠检查异常)的患者进行前列腺癌组织学诊断的标准护理。

J Sex Med:美国前列腺癌幸存者使用睾酮治疗的趋势

关于有前列腺癌(CaP)病史男性使用睾酮疗法(TTh)的医生处方模式没有得到很好的描述。

J Urol:美国真实世界中对转移去势抵抗性前列腺癌患者的管理

转移性前列腺癌(mPC)患者最初通常对手术或药物(雄性激素阻断疗法[ADT])去势有反应,称为转移性去势敏感前列腺癌(mCSPC),未接受ADT而发生转移的患者也认为是mCSPC(原发进展性mCSPC

J Sex Med:枸橼酸西地那非与接受放射治疗前列腺癌患者的生化复发风险:一项随机对照试验的事后分析

枸橼酸西地那非已证明在前列腺放射治疗(RT)的同时和之后对性功能有保护作用,但一些证据表明,前列腺根治术后服用西地那非患者的生化复发(BCR)风险增加。

Lancet Oncol:PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性

Talazoparib在既往治疗过的携带DDR-HRR基因变异的晚期转移性去势抵抗性前列腺癌患者中有持久的抗肿瘤活性